Folate receptor

Bio-Thera Solutions Announces BAT8006 (Folate-Receptor-α-ADC) and BAT8008 (Trop2-ADC) Poster Presentations at the 2022 San Antonio Breast Cancer Symposium

Retrieved on: 
Friday, December 2, 2022
Biotechnology, Other Health, Health, Pharmaceutical, Oncology, Ovarian cancer, Degenerative disease, IND, Breast cancer, Autoimmunity, Folate, Exatecan, Safety, Oslo bid for the 2022 Winter Olympics, Intellectual property, Neoplasm, News, Pharmacy, Cancer, Therapy, ADC, Marketing, WeChat, Stomach, Patient, Engineering, Bystander effect, Folate receptor, Fine chemical, Medical imaging, Fashion, Pharmaceutical industry

Bio-Thera Solutions, a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and a pipeline of biosimilars, today announced the company will present two posters at the 2022 San Antonio Breast Cancer Symposium (SABCS) taking place December 6 - 10, 2022 in San Antonio, Texas.

Key Points: 
  • Bio-Thera Solutions, a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and a pipeline of biosimilars, today announced the company will present two posters at the 2022 San Antonio Breast Cancer Symposium (SABCS) taking place December 6 - 10, 2022 in San Antonio, Texas.
  • Folate Receptor is a naturally occurring receptor that is overexpressed in many types of cancer, including breast cancer and ovarian cancer.
  • Trop-2 is a naturally occurring receptor that is overexpressed in many types of cancer, including triple negative breast cancer and gastric cancer.
  • This news release contains certain forward-looking statements relating to BAT8006, BAT8008 or the product pipelines in general of Bio-Thera Solutions.

Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT8009, an Antibody Drug Conjugate Targeting B7-H3 (CD276) for the Treatment of Advanced Solid Tumors

Retrieved on: 
Tuesday, August 2, 2022
Biotechnology, Other Health, Health, Pharmaceutical, Oncology, Bystander effect, Cell membrane, Large-cell lung carcinoma, Tissue, ADC, Trial of the century, Forward-looking statement, TIGIT, HER2, Research, Intellectual property, Neoplasm, Pharmacy, Marketing, Safety, Cancer, News, OX40, CD276, Clinical trial, WeChat, Drug development, Patient, Pharmacokinetics, Degenerative disease, Breast cancer, Therapy, Autoimmunity, Engineering, Folate receptor, Squamous cell carcinoma, IND, Pharmaceutical industry

The clinical trial is a multicenter, open-label Phase 1 clinical study in patients with advanced solid tumors to evaluate the safety and tolerability of BAT8009 and to determine the recommended phase 2 dose.

Key Points: 
  • The clinical trial is a multicenter, open-label Phase 1 clinical study in patients with advanced solid tumors to evaluate the safety and tolerability of BAT8009 and to determine the recommended phase 2 dose.
  • Differences in expression levels make B7-H3 an potential target for ADC drug development.
  • BAT8009 was developed using Bio-Theras proprietary anti-B7-H3 antibody and ADC linker-payload that includes a cleavable and systemically stable linker and a small molecule topoisomerase I inhibitor.
  • The Phase 1, multi-center, open-label, dose-escalation clinical trial of BAT8009 is designed to assess the safety and tolerability of BAT8009.

Astellas and Sutro Biopharma Announce Worldwide Strategic Collaboration to Advance Novel Immunostimulatory Antibody-Drug Conjugates (iADCs)

Retrieved on: 
Tuesday, June 28, 2022
Merck Serono, BCMA, Patient, ADC, Control, Biotechnology, Modality, Pembrolizumab, Research, Merck Group, BMS, Cancer, COVID-19, Growth, TSE, Immunogenic cell death, Sutro, Goal, Advertising, U.S. Securities and Exchange Commission, Multimedia, Folate receptor, Forward-looking statement, Metastasis, NSCLC, Immune system, Fast Track, Sutro Biopharma, Merck, Partnership, IADC, Security (finance), Environment, Bristol Myers Squibb, Private Securities Litigation Reform Act, Neoplasm, Technology, Antibody, Lymphoid leukemia, Survival, B cell, JD, Risk, NASDAQ, Tumor microenvironment, Multiple myeloma, Cytotoxicity, Large-cell lung carcinoma, Biology, Knowledge, STRO, Protein engineering, Medical imaging, Vaccine, Risk management, Pharmaceutical industry, Astellas Pharma

TOKYO and SOUTH SAN FRANCISCO, Calif., June 27, 2022 /PRNewswire/ --  Astellas Pharma Inc. (TSE: 4503), (President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Sutro Biopharma, Inc. (NASDAQ: STRO), (CEO: William J. Newell, JD, "Sutro") today announced a worldwide, strategic collaboration and licensing agreement focused on the discovery and development of novel immunostimulatory antibody-drug conjugates (iADCs). The collaboration leverages the unique cancer-fighting potential of iADCs as a novel modality, enabled by Sutro's ability to engineer complex conjugated antibodies, and Astellas' global oncology R&D expertise.

Key Points: 
  • The collaboration leverages the unique cancer-fighting potential of iADCs as a novel modality, enabled by Sutro's ability to engineer complex conjugated antibodies, and Astellas' global oncology R&D expertise.
  • Sutro is a leading company in the area of iADCs, a new modality, and has its own original iADC technologies.
  • The strategic partnership with Sutro will help us expand our pipeline and widen the choice of cancer immunotherapies."
  • Sutro Biopharma, Inc. (Sutro), headquartered in South San Francisco, is a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs).

Sutro Biopharma Presents Nonclinical Data for Antibody-Drug Conjugate STRO-002 at the AACR Annual Meeting 2022

Retrieved on: 
Friday, April 8, 2022
BCMA, Private Securities Litigation Reform Act, Company, Fast Track, Orphan, Therapy, Merck Group, Folate receptor, Forward-looking statement, Protein engineering, ADC, Cancer, Vaccine, Biotechnology, Risk, Monoclonal antibody, Celgene, U.S. Securities and Exchange Commission, NSCLC, Ovarian cancer, Security (finance), Lymphoid leukemia, Multiple myeloma, Control, Goal, Merck Serono, COVID-19, Bristol Myers Squibb, FDA, Patient, Large-cell lung carcinoma, Pharmaceutical industry

Sutro Biopharma, Inc., located in South San Francisco, is a clinical-stage drug discovery, development and manufacturing company.

Key Points: 
  • Sutro Biopharma, Inc., located in South San Francisco, is a clinical-stage drug discovery, development and manufacturing company.
  • Using precise protein engineering and rational design, Sutro is advancing next-generation oncology therapeutics.
  • Sutro is dedicated to transforming the lives of cancer patients by creating medicines with improved therapeutic profiles for areas of unmet need.
  • Follow Sutro on Twitter,@Sutrobio, and at www.sutrobio.com to learn more about our passion for changing the future of oncology.

Sutro Biopharma to Present at the 21st Annual Needham Virtual Healthcare Conference

Retrieved on: 
Tuesday, April 5, 2022
BCMA, Fast Track, Orphan, Therapy, NASDAQ, Merck Group, Folate receptor, Protein engineering, ADC, Cancer, STRO, Vaccine, Biotechnology, Conference, Monoclonal antibody, Therapure BioPharma Inc, Celgene, NSCLC, Ovarian cancer, Lymphoid leukemia, Multiple myeloma, Control, Merck Serono, The Company, Bristol Myers Squibb, SAN, FDA, Patient, Large-cell lung carcinoma, Pharmaceutical industry

Sutro Biopharma, Inc., located in South San Francisco, is a clinical-stage drug discovery, development and manufacturing company.

Key Points: 
  • Sutro Biopharma, Inc., located in South San Francisco, is a clinical-stage drug discovery, development and manufacturing company.
  • Using precise protein engineering and rational design, Sutro is advancing next-generation oncology therapeutics.
  • Sutro is dedicated to transforming the lives of cancer patients by creating medicines with improved therapeutic profiles for areas of unmet need.
  • Follow Sutro on Twitter,@Sutrobio, and at www.sutrobio.com to learn more about our passion for changing the future of oncology.

Bio-Thera Solutions Announces First Patient Dosed in a Phase 1 Study in Australia Evaluating BAT6026, an Anti-OX40 Antibody with Enhanced ADCC Effect, in Combination with BAT1308, an Anti-PD-1 Antibody

Retrieved on: 
Wednesday, March 30, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, ADCC, IO, Folate, Therapy, Degenerative disease, Marketing, Trial of the century, Forward-looking statement, Pharmacokinetics, ADC, Autoimmunity, Pharmacology, CD47, IND, Neoplasm, Cancer, Antibody-drug conjugate, CEO, Solution, PD-1, OX40, Safety, TIGIT, Intellectual property, News, Pharmacy, Engineering, Patient, Folate receptor, Vaccine, Pharmaceutical industry

BAT6026 has demonstrated highly potent anti-tumor activity as a single agent and in combination with BAT1308 in in vivo pharmacology studies.

Key Points: 
  • BAT6026 has demonstrated highly potent anti-tumor activity as a single agent and in combination with BAT1308 in in vivo pharmacology studies.
  • BAT6026 has demonstrated potent Treg depletion activity, while synergistically activating T effector cells.
  • Key objectives in the study include determining maximum tolerated dose and recommended Phase 2 dose (RP2D), pharmacokinetics and preliminary anti-tumor activity in combination therapy.
  • This news release contains certain forward-looking statements relating to BAT6026, BAT1308 or the product pipelines in general of Bio-Thera Solutions.

Sutro Biopharma to Participate in the Cowen 42nd Annual Healthcare Conference

Retrieved on: 
Thursday, March 3, 2022
Celgene, Patient, Multiple myeloma, Vaccine, Therapure BioPharma Inc, Merck Group, Baozou Big News Events, Folate receptor, BCMA, Biotechnology, Lymphoid leukemia, Cancer, FDA, SAN, Large-cell lung carcinoma, Webcast, Orphan, ADC, Fast Track, Bristol Myers Squibb, The Company, STRO, Merck Serono, Protein engineering, Control, Ovarian cancer, News, NSCLC, Investor relations, Monoclonal antibody, NASDAQ, Therapy, Pharmaceutical industry

A live webcast of the presentation will be accessible through the News & Events page of the Investor Relations section of the company's website at www.sutrobio.com .

Key Points: 
  • A live webcast of the presentation will be accessible through the News & Events page of the Investor Relations section of the company's website at www.sutrobio.com .
  • Sutro Biopharma, Inc., located in South San Francisco, is a clinical-stage drug discovery, development and manufacturing company.
  • Sutro is dedicated to transforming the lives of cancer patients by creating medicines with improved therapeutic profiles for areas of unmet need.
  • Follow Sutro on Twitter,@Sutrobio, and at www.sutrobio.com to learn more about our passion for changing the future of oncology.

Sutro Biopharma to Present at the 40th Annual J.P. Morgan Virtual Healthcare Conference

Retrieved on: 
Thursday, January 6, 2022
Baozou Big News Events, Orphan, Vaccine, Fast Track, Merck Group, STRO, Large-cell lung carcinoma, Ovarian cancer, Therapy, BCMA, News, Monoclonal antibody, Patient, Webcast, NSCLC, Cancer, The Company, Control, Twitter, Conference, Celgene, Folate receptor, NASDAQ, FDA, Therapure BioPharma Inc, Investor relations, Multiple myeloma, SAN, Merck Serono, Bristol Myers Squibb, Biotechnology, Lymphoid leukemia, ADC, Protein engineering, Pharmaceutical industry

A live webcast of the presentation will be accessible through the News & Events page of the Investor Relations section of the company's website at www.sutrobio.com .

Key Points: 
  • A live webcast of the presentation will be accessible through the News & Events page of the Investor Relations section of the company's website at www.sutrobio.com .
  • Sutro Biopharma, Inc., located in South San Francisco, is a clinical-stage drug discovery, development and manufacturing company.
  • Sutro is dedicated to transforming the lives of cancer patients by creating medicines with improved therapeutic profiles for areas of unmet need.
  • Follow Sutro on Twitter, @Sutrobio , and at www.sutrobio.com to learn more about our passion for changing the future of oncology.

Sutro Biopharma and Tasly Biopharmaceuticals Enter into Exclusive License Agreement for STRO-002 in Greater China

Retrieved on: 
Monday, December 27, 2021
NSCLC, ADC, Cancer, Folate receptor, Twitter, Private Securities Litigation Reform Act, Fast Track, Therapure BioPharma Inc, Forward-looking statement, COVID-19, Orphan, Hematological Cancer Research Investment and Education Act, Triple-negative breast cancer, Clinical trial, Vaccine, U.S. Securities and Exchange Commission, Ovarian cancer, Multiple myeloma, Patient, Bristol Myers Squibb, Large-cell lung carcinoma, Board, TNBC, Company, Celgene, Goal, Yan, Merck Serono, NASDAQ, Perfusion, Therapy, History, Protein engineering, Security (finance), Lymphoid leukemia, STRO, Monoclonal antibody, Conjugation, Risk, Tasly, BCMA, Merck Group, Biotechnology, Control, SAN, Research, FDA, Partnership, Fine chemical, Pharmaceutical industry, Greater China

Sutro retains development and commercial rights of STRO-002 outside of Greater China.

Key Points: 
  • Sutro retains development and commercial rights of STRO-002 outside of Greater China.
  • Upon commercialization, Sutro will receive tiered, double-digit royalties based on annual net sales of STRO-002 in Greater China.
  • Tasly is an excellent partner for our Greater China collaboration, with a history of successful execution for developing and commercializing therapeutics.
  • As a leading innovative biopharmaceutical company in China, Tasly Biopharmaceuticals has a commercialization platform integrating research and development, manufacturing and sales.

Sutro Biopharma to Participate in Two Upcoming Investor Conferences

Retrieved on: 
Monday, November 22, 2021
Patient, Private Securities Litigation Reform Act, NSCLC, Security (finance), Ovarian cancer, Risk, Folate receptor, Forward-looking statement, BCMA, Company, Large-cell lung carcinoma, Cancer, Bristol Myers Squibb, Multiple myeloma, SAN, Merck Serono, U.S. Securities and Exchange Commission, Therapy, Monoclonal antibody, Vaccine, COVID-19, Orphan, Goal, Twitter, Protein engineering, STRO, Merck Group, Biotechnology, Fast Track, ADC, FDA, Lymphoid leukemia, Sutro Biopharma, Celgene, Control, NASDAQ, Investor relations, Pharmaceutical industry

Live webcasts of each presentation can be accessed through the Events and Presentations page of the Investor Relations section on the company's website at www.sutrobio.com .

Key Points: 
  • Live webcasts of each presentation can be accessed through the Events and Presentations page of the Investor Relations section on the company's website at www.sutrobio.com .
  • Sutro Biopharma, Inc., located in South San Francisco, is a clinical-stage drug discovery, development and manufacturing company.
  • Using precise protein engineering and rational design, Sutro is advancing next-generation oncology therapeutics.
  • Follow Sutro on Twitter, @Sutrobio , and at www.sutrobio.com to learn more about our passion for changing the future of oncology.